AlphAIAlphAI — Financial news for AI agents
marketscreener.comAUG 311 min read$AXSM

Axsome Therapeutics Starts Phase 3 Trial of AXS-05 for Smoking Cessation

Axsome Therapeutics has initiated a Phase 3 trial for AXS-05, a treatment aimed at smoking cessation. The company's stock is currently trading at $199.02, with a 5-day change of -3.51% and a year-to-date change of -4.21%. UBS recently adjusted its price target to $280 from $259, maintaining a Buy rating.

Original reporting
marketscreener.com
Published Aug 31, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AXSM
Neutral
medium confidence
Mentioned
$AXSM
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$AXSMNeutralLow
01

Why it matters

The trial start reduces binary risk but does not provide immediate earnings or revenue guidance. Market reaction will depend on interim data releases.

02

Market read

Primary biotech news with modest short‑term trading relevance; longer‑term upside tied to trial outcomes.

03

What to watch

Competing nicotine‑cessation products and regulatory timelines could dampen upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Axsome Therapeutics (AXSM) is a clinical‑stage biopharma focused on central nervous system disorders. AXS-05 is its oral NMDA antagonist‑antidepressant candidate now being tested for smoking cessation.

Company-level read

Ticker impact

$AXSMNeutralMedium confidence
Context

Axsome Therapeutics announced the initiation of a Phase 3 trial for its AXS-05 smoking‑cessation program.

Expected impact

Modest upside potential if interim data are positive; limited immediate move.

Evidence & confidence

Trial start is material for a biotech but no data yet; market may price in long‑term upside.

Market effects

Sector

Adds to the pipeline momentum in the smoking‑cessation therapeutic space.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking biotech pipelines.

Counterpoint

What could challenge this read

Phase 3 failures are common; investors may wait for data before committing.

Key entities

  • Company
    Axsome Therapeutics

    US‑listed biotech developing AXS‑05.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 20
$AXSMMed

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

Axsome Therapeutics (NASDAQ:AXSM) presented at the H.C. Wainwright Conference, highlighting growth for Auvelity, with estimated peak sales of over $8 billion. Sunosi and SYMBRAVO also showed potential, with peak sales estimates of $300M-$500M and $500M-$1B, respectively. The company has multiple pipeline milestones and expects annual NDA filings through 2031. Axsome reported $320M in cash and expects profitability soon.

yahoo.com2 min
SEP 12
$AXSMMedAI 8/10

Should First Patient Dosed Require Action From Axsome Therapeutics Stock Investors?

Axsome Therapeutics (AXSM) dosed the first patient in a Phase 3 trial (SUMMIT) for AXS-05 in smoking cessation. The trial compares AXS-05 to bupropion and placebo, with abstinence at week 12 as the primary endpoint. Success could expand AXS-05's use and leverage its patent estate until 2043. Analysts project $2.5B revenue and $908.3M earnings by 2029, but risks include cash burn and trial execution.

simplywall.st3 min
SEP 6
$AXSMMedAI 8/10

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following AXS-05 Phase 3 Smoking Trial Launch

Axsome Therapeutics (AXSM) has initiated a Phase 3 trial for AXS-05 in smoking cessation, aiming to expand its use beyond existing approvals. The trial's success could enhance the company's long-term outlook, though near-term focus remains on commercializing Auvelity, Sunosi, and SYMBRAVO. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside.

simplywall.st3 min